Based on that, we further validated the predictive function of m6A score in response to immune checkpoint inhibitors in an anti-PD-L1 cohort (IMvigor210) in urinary carcinoma, which was an alternative cohort with consistent conclusions from the TCGA bladder cancer (BLCA) cohort. This evidence concerns the gene CD274 and urinary bladder cancer.